Literature DB >> 18316544

Gemcitabine resistance in pancreatic cancer: picking the key players.

Michael P Kim, Gary E Gallick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18316544     DOI： 10.1158/1078-0432.CCR-07-2247

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  61 in total

1.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

2.  Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.

Authors:  Yong-Wei Wang; Shuang-Jia Wang; Yi-Nan Zhou; Shang-Ha Pan; Bei Sun
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-24       Impact factor: 4.553

3.  Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine.

Authors:  Congying Chen; Wenqin Xiao; Li Huang; Ge Yu; Jianbo Ni; Lijuan Yang; Rong Wan; Guoyong Hu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

4.  PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation.

Authors:  Manju Kanamala; Brian D Palmer; Hamidreza Ghandehari; William R Wilson; Zimei Wu
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

Review 5.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.

Authors:  Li Ding; Vijay S Madamsetty; Spencer Kiers; Olga Alekhina; Andrey Ugolkov; John Dube; Yu Zhang; Jin-San Zhang; Enfeng Wang; Shamit K Dutta; Daniel M Schmitt; Francis J Giles; Alan P Kozikowski; Andrew P Mazar; Debabrata Mukhopadhyay; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2019-09-18       Impact factor: 12.531

7.  Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.

Authors:  Yan Wang; Jung-Mao Hsu; Ya'an Kang; Yongkun Wei; Pei-Chih Lee; Shing-Jyh Chang; Yi-Hsin Hsu; Jennifer L Hsu; Hung-Ling Wang; Wei-Chao Chang; Chia-Wei Li; Hsin-Wei Liao; Shih-Shin Chang; Weiya Xia; How-Wen Ko; Chao-Kai Chou; Jason B Fleming; Huamin Wang; Rosa F Hwang; Yue Chen; Jun Qin; Mien-Chie Hung
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

8.  Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.

Authors:  Cheng Xu; Yunfei Wang; Qiu Tu; Zhiye Zhang; Mengrou Chen; James Mwangi; Yaxiong Li; Yang Jin; Xudong Zhao; Ren Lai
Journal:  Oncogene       Date:  2018-10-24       Impact factor: 9.867

Review 9.  Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.

Authors:  O E Rahma; A Duffy; D J Liewehr; S M Steinberg; T F Greten
Journal:  Ann Oncol       Date:  2013-05-12       Impact factor: 32.976

10.  Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers.

Authors:  Kenji Yokoi; Biana Godin; Carol J Oborn; Jenolyn F Alexander; Xuewu Liu; Isaiah J Fidler; Mauro Ferrari
Journal:  Cancer Lett       Date:  2012-09-18       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.